Company: AEMD
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001683168-25-006049
Chunk: 11

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-13
Form: 10-Q
Item: Item 1
Chunk 11
---
 Australia evaluating the Hemopurifier in oncology
patients. The current period also includes expenses related to preclinical studies supporting potential new indications, including work
conducted in partnership with UCSF’s Long COVID Clinic and internal lab activities targeting platelet-derived extracellular vesicles
and transplant-related applications. These initiatives are part of our broader strategy to expand the therapeutic potential of the Hemopurifier
beyond viral pathogens and support future regulatory submissions. We expect R&D expenses to continue to fluctuate based on the timing
and scale of future clinical trial activity and internal development efforts. Our
research and development expenses in those periods were as follows:

    Schedule of research and development
expenses 

    June 30,  
    June 30, 

    2025  
    2024 
  
    Three months ended 
    $524,368  
    $414,658 

4. RECENT ACCOUNTING PRONOUNCEMENTS

In December 2023, the FASB issued Accounting Standards
Update 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires enhanced annual disclosures related to
tax rate reconciliation and income taxes paid disaggregated by federal, state and foreign taxes. ASU 2023-09 is effective for the Company
for annual periods beginning on or after April 1, 2025. The Company maintains a full valuation allowance against its deferred assets and
does not have current income tax expense nor material income taxes paid. While the Company is evaluating the impact of this new standard
on its income tax disclosures, it does not expect the adoption of ASU 2023-09 to have material impact on its consolidated financial statements,
as the amendments relate to disclosures only.

In
March 2024, the FASB issued Accounting Standards Update 2024-03, Income Statement—Reporting Comprehensive Income—Expense
Disaggregation Disclosures (“ASU 2024-03”), which requires public business entities to provide enhanced annual and
interim disclosures that disaggregate specified income statement expense categories. ASU 2024-03 is effective for annual periods beginning
after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. The Company is evaluating whether
the adoption of this new standard will have a material impact on our disclosures.

In
March 2024, the Financial Accounting Standards Board (FASB) issued Accounting Standards